Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00836381 |
Recruitment Status
:
Completed
First Posted
: February 4, 2009
Last Update Posted
: May 30, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
For many years, antimuscarinics have been first-line pharmacological treatment for OAB. A recent meta-analysis of randomised, controlled trials on antimuscarinic treatment of OAB concluded that the drugs provide significant improvements in OAB symptoms compared with placebo but that the benefits are of limited clinical significance. The analysis questioned the clinical significance of the trial results, one reason for which was the lack of data on the use of sensitive patient-driven criteria. Traditional symptomatic and urodynamic measures of treatment success may be meaningful to clinicians but often have little meaning to patients. Therefore, patient-reported outcomes (PROs), which provide a subjective measure of a patient's response to treatment, are useful. Recently, clinicians treating OAB have begun to recognize the value of PROs but still overlook the treatment efficacy in terms of patient-reported goal achievement (PGA).
Patients with OAB have combination of symptoms and the extent to which individual OAB symptoms affect patients varies. Also each patient can have different goal for the treatment. Therefore, assessing the degree of goal achievement in each patient can provide a new aspect of treatment benefit.
This controlled study will advance the understanding of OAB in terms of patient-centered treatments goals and goal achievement and will provide a new aspect of treatment benefit.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Overactive Bladder | Drug: Tolterodine extended-release (ER) 4mg Drug: Placebo | Phase 4 |
-
Objectives
- Primary objective: To explore the "Patient-reported Goal Attainment (PGA)" after 12 weeks of treatment with tolterodine extended-release (ER) 4mg in female overactive bladder (OAB) patients.
- Secondary objective: To explore the patient-reported treatment goals and the efficacy of tolterodine on the patient-reported outcomes (PROs), micturition diary parameters, and safety parameters from baseline to 12 weeks of treatment in female OAB patients.
-
Specific aim
: To compare the efficacy of tolterodine ER 4mg with that of placebo, on PROs in terms of PGA after 12 weeks of treatment in female OAB patients.
-
Experimental/research design
- 12-week randomized, placebo-controlled, double-blind, parallel-group, prospective study in Korean women with symptoms of OAB
- Treatment: Each patient will receive tolterodine ER (4 mg, qd) or placebo (randomized in the ratio of 1:1) for 12 weeks.
- Time schedule Start date: 01/Jan/2009 Finish date: 01/Sep/2009 Duration of washout: 7 days Duration of run-in: 7 days Duration of enrollment period: 5 months Duration of treatment period: 12 weeks Completion of analysis: 6 weeks
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 56 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ) |
Study Start Date : | February 2009 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Tolterodine ER
Tolterodine ER 4mg once daily
|
Drug: Tolterodine extended-release (ER) 4mg
Tolterodine extended-release (ER) 4mg once daily for 12 weeks
Other Name: Detrusitol ER 4mg
|
Placebo Comparator: Placebo
Placebo once daily
|
Drug: Placebo
Identical Placebo once daily
|
- Percentage of goal attainment using visual analog scale (VAS) at visit 3 and 4 [ Time Frame: visit 3 (treatment 4 weeks) and 4 (treatment 12 weeks) ]
- Assessment of patient-reported treatment goal [ Time Frame: visit 3 (treatment 4 weeks) and 4 (treatment 12 weeks) ]
- Patient-reported outcomes [ Time Frame: visit 3 (treatment 4 weeks) and 4 (treatment 12 weeks), ]
- Micturition diary efficacy parameters [ Time Frame: visit 3 (treatment 4 weeks) and 4 (treatment 12 weeks), ]
- Safety parameters [ Time Frame: visit 3 (treatment 4 weeks) and 4 (treatment 12 weeks), ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female aged ≥ 18 and ≤ 80 years
-
Symptoms of OAB as verified by the screening 3 day micturition diary, defined by:
Mean urinary frequency ≥8 times/24 hours Mean number of urgency episodes ≥ 2 episode/24 hours
- Symptoms of OAB for ≥ 3 months.
- Ability and willingness to correctly complete the micturition diary and questionnaire
- Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits
Exclusion Criteria:
- Subjects with stress incontinence or mixed stress/urge incontinence where stress incontinence is the predominant component based on prior history.
- Significant hepatic or renal disease, defined as having twice the upper limit of the reference range for serum concentrations of aspartate amino- transferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase or creatinine.
- Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrow-angled glaucoma, urinary retention or gastric retention
- Symptomatic acute urinary tract infection (UTI) during the run-in period
- Recurrent UTI defined as having been treated for symptomatic UTI > 4 times in the last year
- Diagnosed or suspected interstitial cystitis
- Clinically significant bladder outlet obstruction or poor detrusor function defined by clinical symptoms and investigator's opinion according to local standard of care
- Previous history of major urethral and/or bladder surgery
- History of radiation treatment (external or interstitial) to pelvic organs or external genitalia for any reason.
- Subjects with neuropathology that could affect the lower urinary tract or nerve supply
- Patients with marked cystocele or other clinically significant pelvic prolapse.
- Subjects with current (within 2 years) urogenital neoplasms or malignancies including bladder, uterine or cervical cancer
- Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with: Any anticholinergic drugs other than trial drug Any drug treatment for overactive bladder
- On an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
- Subjects currently taking tricyclic antidepressants, diuretics or alpha blockers who have not been on a stable dose of these medications for at least one month
- Current administration of a selective serotonin reuptake inhibitor (SSRI) and has not been on a stable dose for at least three months
- Receipt of any electrostimulation or bladder training within the 14 days before randomization, or expected to start such treatment during the study
- An indwelling catheter or practicing intermittent self-catheterization
- Use of any investigational drug within 1 months preceding the start of the study
- Patients with chronic constipation or history of severe constipation
- Pregnant or nursing women
- Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study start and not agreeing to use such methods during the entire study period and for at least 1 month thereafter *Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives and surgical procedures (tubal ligation or vasectomy).
- Any other condition which makes the patient unsuitable for inclusion.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00836381
Korea, Republic of | |
Samsung Medical Center | |
Seoul, Korea, Republic of |
Principal Investigator: | Kyu-Sung Lee, Ph.D | Samsung Medical Center |
Responsible Party: | KYU-SUNG LEE, Proffesor, Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00836381 History of Changes |
Other Study ID Numbers: |
2008-09-006 |
First Posted: | February 4, 2009 Key Record Dates |
Last Update Posted: | May 30, 2013 |
Last Verified: | May 2013 |
Keywords provided by KYU-SUNG LEE, Samsung Medical Center:
Overactive bladder Antimuscarinics Patient-reported goal achievement |
Additional relevant MeSH terms:
Urinary Bladder, Overactive Urinary Bladder Diseases Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations Signs and Symptoms Tolterodine Tartrate |
Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents |